Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Roger S McIntyre. (2017) The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatric Disease and Treatment 13, pages 2913-2919.
Read now
Read now
Sang-Eun Choi, Mélanie Brignone, Seong Jin Cho, Hong Jin Jeon, Rangrhee Jung, Rosanne Campbell, Clément Francois & Dominique Milea. (2016) Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Review of Pharmacoeconomics & Outcomes Research 16:5, pages 629-638.
Read now
Read now
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Federica Vellante, Michele Fornaro, Annastasia Fiengo, Monica Mazza, Roberta Vecchiotti, Giampaolo Perna, Andrea de Bartolomeis, Giovanni Martinotti, Massimo Di Giannantonio & Domenico De Berardis. (2016) New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics 16:5, pages 483-495.
Read now
Read now
Philip F Saltiel & Daniel I Silvershein. (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatric Disease and Treatment 11, pages 875-888.
Read now
Read now
David J Hellerstein & Joseph Flaxer. (2015) Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evidence 10, pages 49-62.
Read now
Read now
Susan G Kornstein, Roger S McIntyre, Michael E Thase & Matthieu Boucher. (2014) Desvenlafaxine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy 15:10, pages 1449-1463.
Read now
Read now
Articles from other publishers (27)
O. M. Drapkina, O. V. Grigorova, O. N. Dzhioeva, G. P. Kostyuk, N. G. Neznanov, M. A. Samushiya & V. P. Chulanov. (2022) The resolution of the Expert Council on the Diagnosis, Treatment, and Prevention of Symptoms of Depression in Outpatients with New Coronavirus Infection. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY 56:4, pages 112-123.
Crossref
Crossref
Sergio De Filippis, Ginevra Lombardozzi, Marta Matrone, Emanuela Amici, Giada Trovini, Filippo Perrini, Alessandro Di Giovanni, Valeria Giovanetti & Georgios D. Kotzalidis. (2022) Differential Response to Three Antidepressants in Patients with Major
Depressive Episode Who Suffered Covid-19-Related Trauma. Current Neuropharmacology 20:12, pages 2393-2407.
Crossref
Crossref
Matej Ľupták, Zdeněk Fišar & Jana Hroudová. (2022) Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study. International Journal of Molecular Sciences 23:22, pages 13824.
Crossref
Crossref
Haihua Tian, Zhenyu Hu, Jia Xu & Chuang Wang. (2022) The molecular pathophysiology of depression and the new therapeutics. MedComm 3:3.
Crossref
Crossref
Orkid Coskuner-Weber, Ozan Mirzanli & Vladimir N. Uversky. (2022) Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases. Biophysical Reviews 14:3, pages 679-707.
Crossref
Crossref
Sagar Karia, Avinash De Sousa & Ruksheda Syeda. (2021) A “Real-World” Chart Review Study of Monotherapy and Adjunctive Vortioxetine in Clinical Practice. Indian Journal of Private Psychiatry 14:2, pages 92-94.
Crossref
Crossref
Natalie T Mills, Emma Sampson, Célia Fourrier & Bernhard T Baune. (2021) Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. International Journal of Neuropsychopharmacology 24:4, pages 314-321.
Crossref
Crossref
Yulu Zhang, Yu Long, Shuang Yu, Dan Li, Ming Yang, Yongmei Guan, Dingkun Zhang, Jinyan Wan, Songyu Liu, Ai Shi, Nan Li & Wei Peng. (2021) Natural volatile oils derived from herbal medicines: A promising therapy way for treating depressive disorder. Pharmacological Research 164, pages 105376.
Crossref
Crossref
Rongkai Du, Juan Xu, Jing Li, Lei Zhang, Lifeng Ning & Shan Li. (2021)
Pharmaceutical salt and salt hydrates of vortioxetine with sulfonic acid to ameliorate the solubility and hygroscopicity
via
the charge-assisted hydrogen bond assembly
. New Journal of Chemistry 45:3, pages 1474-1481.
Crossref
Crossref
I. V. Oleichik, T. I. Shishkovskaia & P. A. Baranov. (2020) Contemporary approaches to correction of cognitive impairment in endogenous depression. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY:4, pages 82-93.
Crossref
Crossref
I. Kandilarov, N. Vilmosh, M. Georgieva-Kotetarova, H. Zlatanova & D. Delev. (2020) P.433 Experimental study of the antinociceptive effect of vortioxetine. European Neuropsychopharmacology 40, pages S246.
Crossref
Crossref
Andrea Fagiolini, Umberto Albert, Laura Ferrando, Erik Herman, Cosmina Muntean, Eva Pálová, Agnese Cattaneo, Alessandro Comandini, Giorgio Di Dato, Giorgio Di Loreto, Luisa Olivieri, Enrica Salvatori, Serena Tongiani & Siegfried Kasper. (2020) A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. International Clinical Psychopharmacology 35:3, pages 137-146.
Crossref
Crossref
Sakine Atila Karaca, Nurana Rashidova, Alper Uğur & Duygu Yeniceli Uğur. (2019) Development of a simple HPLC method for the quantitation of vortioxetine in pharmaceuticals using DoE approach. Chemical Papers 74:5, pages 1541-1549.
Crossref
Crossref
Daniela Adamo, Giuseppe Pecoraro, Massimo Aria, Gianfranco Favia & Michele Davide Mignogna. (2019) Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study. Pain Medicine.
Crossref
Crossref
Alaeddine Djillani, Mariel Pietri, Jean Mazella, Catherine Heurteaux & Marc Borsotto. (2019) Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacology & Therapeutics 194, pages 185-198.
Crossref
Crossref
Anish Shah & Joanne Northcutt. (2018) An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder. Annals of General Psychiatry 17:1.
Crossref
Crossref
Xiangqing Xu, Yaqin Wei, Qiang Guo, Song Zhao, Zhiqiang Liu, Ting Xiao, Yani Liu, Yinli Qiu, Yuanyuan Hou, Guisen Zhang & KeWei Wang. (2018)
Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT
2A
Antagonist Activity for the Treatment of Depression
. Journal of Pharmacology and Experimental Therapeutics 365:3, pages 624-635.
Crossref
Crossref
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R. Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka & Magdalena Koperny. (2017) Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 69:4, pages 595-601.
Crossref
Crossref
Yeshwant Kurhe, R. Mahesh & Thangaraj Devadoss. (2017) Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology 234:7, pages 1165-1179.
Crossref
Crossref
Andrew H. Dawson. 2017. Critical Care Toxicology. Critical Care Toxicology
1027
1039
.
Paula L. Jacobsen, Atul R. Mahableshwarkar, William A. Palo, Yinzhong Chen, Marianne Dragheim & Anita H. Clayton. (2015) Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectrums 21:5, pages 367-378.
Crossref
Crossref
G. Neri, C. Serrati, P. Zolo, N. Cataldo & C. Ripellino. (2016) Italian neurologists’ perception on cognitive symptoms in major depressive disorder. Neurological Sciences 37:9, pages 1437-1442.
Crossref
Crossref
Lei Liu, Na Cao, Xingling Ma, Kaihe Xiong, Lili Sun, Qiaogen Zou & Lili Yao. (2016) Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC–MS, IR and NMR. Journal of Pharmaceutical and Biomedical Analysis 117, pages 325-332.
Crossref
Crossref
Andrew H. Dawson. 2016. Critical Care Toxicology. Critical Care Toxicology
1
13
.
Gin S Malhi, Darryl Bassett, Philip Boyce, Richard Bryant, Paul B Fitzgerald, Kristina Fritz, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard Porter & Ajeet B Singh. (2015) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry 49:12, pages 1087-1206.
Crossref
Crossref
Olivia F. O’Leary, Timothy G. Dinan & John F. Cryan. (2015) Faster, better, stronger: Towards new antidepressant therapeutic strategies. European Journal of Pharmacology 753, pages 32-50.
Crossref
Crossref
Jian-Yang Lin, Ming-Yan Jiang, Zhou-Mi Kan & Yang Chu. (2014) Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis. Journal of Affective Disorders 168, pages 430-438.
Crossref
Crossref